Stefanos Grammatikos is heading Biotech Sciences, the CMC Development organization he helped build at UCB, originally to support the company’s growing biologics portfolio and more recently to facilitate its entry into gene therapy. Prior to joining UCB (2008), Stefanos held several leadership positions in bioprocess development and biologics manufacturing at Boehringer Ingelheim Pharma in Germany. As early as 1998 he realized the importance of cell line development to biopharmaceutical manufacturing and initiated at BI a pioneering concept for clone selection including FACS and early high-throughput automation. Stefanos holds a BS degree in Chemical Engineering from the University of California at Berkeley and MS and PhD degrees in Biochemical Engineering from Northwestern University. In recognition of his contribution and service to the Animal Cell Technology community, he was awarded in 2015 the Medal of the European Society for Animal Cell Technology (ESACT). Since 2017 he is an elected member of the ESACT Executive Committee.